Bioptimus, a leading company in artificial intelligence for biology, has announced a significant advancement with the launch of M-Optimus, the first AI model designed to integrate multiple biological data types and simulate complex biological systems. The company is providing early access to a select group of pioneer clients while also enhancing availability of its top-rated pathology model, H-Optimus-1, through a special program in partnership with Amazon SageMaker AI. Until now, most AI models and biological research have focused on a single data type, such as genetic sequences or medical imaging, which has limited the understanding and application of biology in healthcare. Bioptimus envisions M-Optimus as a universal framework that can model cells, tissues, and patients across diverse diseases and populations, providing a comprehensive view of biology that can accelerate research and improve patient outcomes. The first version of M-Optimus combines hematoxylin and eosin stained histology images, bulk RNA sequencing, spatial transcriptomics, and clinical data into a single model. This is the first AI model in the world to merge multiple biological modalities at this scale and it was trained on one of the largest proprietary datasets, covering millions of patients, more than 50 organ types, and hundreds of medical centers. M-Optimus can accelerate drug discovery and clinical trial design by predicting patient response, helping pharmaceutical companies identify the most promising drug candidates and suitable patients, potentially saving years and millions of dollars.
Health Technology Insights: MHK Launches SmartProminence AI Solutions
It can also predict gene expression, treatment responses, and clinical outcomes directly from histology and multimodal data, offering deeper insights from limited clinical samples. Additionally, companies and hospitals can fine-tune M-Optimus with proprietary data to build tailored models while protecting sensitive information. The AI can create digital twins and simulate clinical trials, which reduces trial time and costs and allows researchers to optimize patient enrollment and therapy modeling. Bioptimus currently provides M-Optimus to a select number of early-access partners and top pharmaceutical companies have already joined, leveraging the model for key research workflows. Jean-Philippe Vert, CEO and co-founder of Bioptimus, stated that M-Optimus represents the first critical step in decoding biology by combining multiple modalities at scale and that the early access program will allow visionary companies to translate this scientific capability into breakthroughs that improve patient care. In addition to M-Optimus, Bioptimus continues to advance AI for histopathology through H-Optimus-1, which is recognized as a state-of-the-art model trained on millions of whole-slide images for cancer grading and biomarker detection. With nearly one million downloads, Bioptimus has partnered with Amazon SageMaker AI to enable researchers, labs, and industry players to deploy H-Optimus-1 securely in the cloud with data privacy, simple billing, and easy access.
Health Technology Insights: Artera Secures $65Million Growth Investment and Reaches $100Million CARR
Bioptimus strengthens its offerings through collaborations with AWS, HuggingFace, NVIDIA, Owkin, and Proscia and is driven by a world-class team, with over half of its staff holding PhDs from top institutions such as MIT, ETH, ENS, and TUM, and leadership with experience from Google Brain, DeepMind, Owkin, and Tempus.
Health Technology Insights: First Stop Health Joins ParetoHealth Network
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
